Mario Sánchez-Borges1, Ignacio J Ansotegui2. 1. Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad and Clínica El Avila, Caracas, Venezuela. 2. Department of Allergy and Immunology, Hospital Quironsalud, Bizkaia, Bilbao, Spain.
Abstract
PURPOSE OF REVIEW: This article presents an update on the clinical pharmacology, mechanisms of action, and safety of second generation antihistamines (SGAHs). RECENT FINDINGS: Recent research has shown the efficacy and good tolerance of SGAHs supporting its indication as first line medications for the treatment of allergic rhinoconjunctivitis and urticaria. SUMMARY: The information contained in this review is relevant for the correct utilization of SGAHs by practicing physicians who take care of these highly prevalent clinical disorders.
PURPOSE OF REVIEW: This article presents an update on the clinical pharmacology, mechanisms of action, and safety of second generation antihistamines (SGAHs). RECENT FINDINGS: Recent research has shown the efficacy and good tolerance of SGAHs supporting its indication as first line medications for the treatment of allergic rhinoconjunctivitis and urticaria. SUMMARY: The information contained in this review is relevant for the correct utilization of SGAHs by practicing physicians who take care of these highly prevalent clinical disorders.
Authors: Grzegorz Kardas; Michał Panek; Piotr Kuna; Janusz Cieszyński; Przemysław Kardas Journal: Front Pharmacol Date: 2020-05-21 Impact factor: 5.810